Bright Minds Biosciences Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Bright Minds Biosciences Inc. (DRUG)
NEW YORK CITY, NY / ACCESS Newswire / November 3, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Bright Minds Biosciences Inc. ("Bright Minds Biosciences Inc.") (NASDAQ:DRUG) concerning potential violations of the federal securities laws.
Bright Minds Biosciences Inc. shares fell sharply after the U.S. Food and Drug Administration placed a partial clinical hold on the Company's planned Phase 2 BMB-101 trial for epilepsy and developmental and epileptic encephalopathies. The regulatory action was not related to earnings or financial performance, but instead stemmed from preclinical toxicity findings in mice as well as inadequate pharmacokinetic and juvenile-toxicity data to support pediatric enrollment. Following the regulatory action, the Company stated that the partial hold was limited strictly to the planned U.S. trial and did not impact any of its other ongoing clinical trials. Bright Minds Biosciences Inc. also stated that it disagreed with the FDA's interpretation of the preclinical mouse findings, though that disagreement did not resolve the agency's regulatory concerns. Additionally, the Company stated that it was awaiting the full formal letter from the FDA and acknowledged that additional data or clinical studies might be required to address the hold. A comprehensive analysis of SEC filings showed no affirmative statements by the Company regarding BMB-101 safety, FDA review status, pediatric enrollment, mouse toxicity, or pharmacokinetic data. The investigation concerns whether Bright Minds Biosciences Inc. adequately disclosed preclinical mouse toxicity findings and pharmacokinetic data deficiencies for BMB-101 ahead of the FDA's partial clinical hold.
If you suffered a loss on your Bright Minds Biosciences Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
SOURCE: Levi & Korsinsky, LLP